Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.44 -4.0%	$1.65	$1.41 ▼ $5.01	$8.39M	1.3	34,657 shs	45,284 shs
BTAI BioXcel Therapeutics	$2.99 -0.7%	$3.43	$1.17 ▼ $13.28	$47.87M	0.2	4.78 million shs	1.43 million shs
EMIS Emisphere Technologies	$7.81	$7.81	$4.06 ▼ $9.16	N/A	N/A	N/A	N/A
OMER Omeros	$4.18 -1.9%	$4.04	$2.95 ▼ $13.60	$284.47M	2.37	663,065 shs	1.99 million shs
RAPT Rapt Therapeutics	$19.86 -3.1%	$12.31	$5.67 ▼ $26.56	$328.44M	-0.1	104,511 shs	608,248 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	-6.74%	-10.00%	-11.93%	-49.65%
BTAI BioXcel Therapeutics	0.00%	-3.86%	-42.83%	+86.88%	-70.67%
EMIS Emisphere Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	0.00%	+0.72%	-6.70%	+30.22%	+6.36%
RAPT Rapt Therapeutics	0.00%	+22.44%	+85.26%	+167.29%	+36.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.44 -4.0%	$1.65	$1.41 ▼ $5.01	$8.39M	1.3	34,657 shs	45,284 shs
BTAI BioXcel Therapeutics	$2.99 -0.7%	$3.43	$1.17 ▼ $13.28	$47.87M	0.2	4.78 million shs	1.43 million shs
EMIS Emisphere Technologies	$7.81	$7.81	$4.06 ▼ $9.16	N/A	N/A	N/A	N/A
OMER Omeros	$4.18 -1.9%	$4.04	$2.95 ▼ $13.60	$284.47M	2.37	663,065 shs	1.99 million shs
RAPT Rapt Therapeutics	$19.86 -3.1%	$12.31	$5.67 ▼ $26.56	$328.44M	-0.1	104,511 shs	608,248 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	-6.74%	-10.00%	-11.93%	-49.65%
BTAI BioXcel Therapeutics	0.00%	-3.86%	-42.83%	+86.88%	-70.67%
EMIS Emisphere Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	0.00%	+0.72%	-6.70%	+30.22%	+6.36%
RAPT Rapt Therapeutics	0.00%	+22.44%	+85.26%	+167.29%	+36.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	976.39% Upside
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$39.75	1,229.43% Upside
EMIS Emisphere Technologies	0.00	N/A	N/A	N/A
OMER Omeros	2.83	Moderate Buy	$18.00	330.62% Upside
RAPT Rapt Therapeutics	2.50	Moderate Buy	$21.57	8.62% Upside

Current Analyst Ratings Breakdown

Latest BTAI, APRE, OMER, RAPT, and EMIS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/3/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/28/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/26/2025	BTAI BioXcel Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/22/2025	RAPT Rapt Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$10.00
8/15/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/15/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Neutral	$8.00 ➝ $9.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$51.00 ➝ $38.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00

(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	5.60	N/A	N/A	$3.55 per share	0.41
BTAI BioXcel Therapeutics	$2.27M	21.09	N/A	N/A	($30.01) per share	-0.10
EMIS Emisphere Technologies	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
RAPT Rapt Therapeutics	$1.53M	214.70	N/A	N/A	$11.51 per share	1.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	N/A	N/A	N/A	-1,645.01%	-78.90%	-62.67%	11/6/2025 (Estimated)
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	11/13/2025 (Estimated)
EMIS Emisphere Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OMER Omeros	-$156.82M	-$2.11	N/A	N/A	N/A	N/A	N/A	-55.49%	11/12/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	11/11/2025 (Estimated)

Latest BTAI, APRE, OMER, RAPT, and EMIS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	OMER Omeros	-$0.55	-$0.53	+$0.02	-$0.43	$0.31 million	$28.60 million
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
EMIS Emisphere Technologies	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.34
BTAI BioXcel Therapeutics	N/A	0.76	0.74
EMIS Emisphere Technologies	N/A	N/A	N/A
OMER Omeros	N/A	0.81	0.81
RAPT Rapt Therapeutics	N/A	13.25	13.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
BTAI BioXcel Therapeutics	30.68%
EMIS Emisphere Technologies	N/A
OMER Omeros	48.79%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
BTAI BioXcel Therapeutics	21.20%
EMIS Emisphere Technologies	72.90%
OMER Omeros	12.90%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
BTAI BioXcel Therapeutics	90	16.01 million	12.62 million	Optionable
EMIS Emisphere Technologies	6	N/A	N/A	Not Optionable
OMER Omeros	210	68.06 million	59.28 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

BTAI, APRE, OMER, RAPT, and EMIS Headlines

Recent News About These Companies

Rapt Therapeutics $RAPT Position Decreased by AJU IB Investment Co. Ltd.

September 19 at 7:43 AM | marketbeat.com

Rapt Therapeutics $RAPT Shares Sold by Medicxi Ventures Management Jersey Ltd

September 16, 2025 | marketbeat.com

Rapt Therapeutics $RAPT Shares Bought by Comerica Bank

September 15, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street Zen

September 15, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Average Recommendation of "Moderate Buy" from Analysts

September 13, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 11, 2025 | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Wall Street Zen

September 8, 2025 | marketbeat.com

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

August 27, 2025 | globenewswire.com

Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet

August 18, 2025 | zacks.com

Rapt Therapeutics price target raised to $9 from $8 at UBS

August 12, 2025 | msn.com

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

August 12, 2025 | zacks.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board

July 15, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BTAI, APRE, OMER, RAPT, and EMIS Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.44 -0.06 (-4.00%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$1.48 +0.04 (+2.43%)

As of 09/19/2025 07:29 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

BioXcel Therapeutics NASDAQ:BTAI

$2.99 -0.02 (-0.66%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$2.96 -0.04 (-1.17%)

As of 09/19/2025 07:57 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Emisphere Technologies OTCMKTS:EMIS

$7.81 0.00 (0.00%)

As of 12/9/2020

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Omeros NASDAQ:OMER

$4.18 -0.08 (-1.88%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$4.26 +0.09 (+2.03%)

As of 09/19/2025 07:59 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Rapt Therapeutics NASDAQ:RAPT

$19.86 -0.64 (-3.12%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$19.56 -0.30 (-1.51%)

As of 09/19/2025 06:30 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, APRE, OMER, RAPT, and EMIS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, APRE, OMER, RAPT, and EMIS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, APRE, OMER, RAPT, and EMIS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BTAI, APRE, OMER, RAPT, and EMIS Company Descriptions

Aprea Therapeutics NASDAQ:APRE

BioXcel Therapeutics NASDAQ:BTAI

Emisphere Technologies OTCMKTS:EMIS

Omeros NASDAQ:OMER

Rapt Therapeutics NASDAQ:RAPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools